Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancer

This week's update covers one new registry entry for Incyte.

• Incyte registered a Phase 3 trial called "MAESTRA 3" (NCT07797283) testing INCB123667 administered at a protocol defined dose alongside bevacizumab¹, compared with bevacizumab plus placebo, in patients with newly diagnosed, histologically confirmed, FIGO Stage III or IV, high-grade serous, high-grade endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer¹ whose tumors overexpress cyclin E1¹. The study is planned to enroll 590 participants¹, and its primary endpoint is progression-free survival by blinded independent central review, measured over approximately 5 years¹. The trial is listed as not yet recruiting, with an estimated start date of December 2026 and estimated primary completion in May 2032¹.